Colorectal cancer screening with fecal occult blood test: A 22‑year cohort study

Jin,Peng; Wu,Zi‑Tao; Li,Shi‑Rong; Li,Shu‑Jun; Wang,Ji‑Heng; Wang,Zhi‑Hong; Lu,Jian‑Guo; Cui,Xin‑Juan; Han,Ying; Rao,Jianyu; Sheng,Jian‑Qiu

doi:10.3892/ol.2013.1402

Colorectal cancer screening with fecal occult blood test: A 22‑year cohort study

Authors:
- Peng Jin
- Zi‑Tao Wu
- Shi‑Rong Li
- Shu‑Jun Li
- Ji‑Heng Wang
- Zhi‑Hong Wang
- Jian‑Guo Lu
- Xin‑Juan Cui
- Ying Han
- Jianyu Rao
- Jian‑Qiu Sheng
View Affiliations

Affiliations: Department of Gastroenterology, Beijing Military General Hospital, Beijing 100700, P.R. China, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90015, USA
Published online on: June 14, 2013 https://doi.org/10.3892/ol.2013.1402
Pages: 576-582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the efficacy of colorectal cancer (CRC) screening with a three‑tier fecal occult blood test (FOBT) in the Chinese population. The study was performed between 1987 and 2008 at the Beijing Military General Hospital, in a cohort of army service males and females aged >50 years. Between 1987 and 2005, a three‑tier screening program, comprising guaiac‑based FOBTs (gFOBTs), followed by immunochemical FOBTs for positive guaiac test samples and then colonoscopy for positive immunochemical test subjects, was performed annually. The cohort was followed up until 2008. The cohort included 5,104 subjects, of which, 3,863 subjects participated in screening (screening group) and 1,241 did not (non‑screening group). The two groups did not differ in age, gender or other major risk factors for colon cancer. Overall, 36 CRCs occurred in the screening group and 21 in the non‑screening group. Compared with the non‑screening group, the relative risk for the incidence and mortality of CRC was 0.51 [95% confidence interval (CI), 0.30‑0.87] and 0.36 (95% CI, 0.18‑0.71), respectively, in the screening group. The general sensitivity of this three‑tier FOBT was 80.6% (95% CI, 65.3‑91.1). Thus, annual screening using the three‑tier FOBT program may reduce the CRC incidence and mortality rate.

View Figures

View References

1.	Stewart BW and Kleihues P: World cancer report. Lyon: IARC Press; pp. 163–166. 2003
2.	Zhang SW, Chen WQ, Kong LZ, Li LD, Lu FZ, Li GL, Meng J and Zhao P: An analysis of cancer incidence and mortality from 30 cancer registries in China, 1998∼2002. Zhongguo Zhongliu. 15:430–448. 2006.
3.	Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, Johnson D, Johnson CD, et al American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 134:1570–1595. 2008. View Article : Google Scholar
4.	Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM and Ederer F: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 328:1365–1371. 1993. View Article : Google Scholar : PubMed/NCBI
5.	Kronborg O, Fenger C, Olsen J, Jorgensen OD and Søndergaard O: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 348:1467–1471. 1996. View Article : Google Scholar : PubMed/NCBI
6.	Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD and Mangham CM: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 348:1472–1477. 1996. View Article : Google Scholar : PubMed/NCBI
7.	Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, Schwartz JS, Ransohoff DF and Selby JV: Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 99:1462–1470. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Allison JE, Tekawa IS, Ransom LJ and Adrain AL: A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 334:155–159. 1996. View Article : Google Scholar : PubMed/NCBI
9.	Li S, Nie Z, Li N, Li J, Zhang P, Yang Z, Mu S, Du Y, Hu J, Yuan S, Qu H, et al: Colorectal cancer screening for the natural population of Beijing with sequential fecal occult blood test: a multicenter study. Chin Med J (Engl). 116:200–202. 2003.PubMed/NCBI
10.	Li S, Wang H, Hu J, Li N, Liu Y, Wu Z, Zheng Y, Wang H, Wu K, Ye H and Rao J: New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: Results of a prospective multicenter study in Chinese patients. Int J Cancer. 118:3078–3083. 2006. View Article : Google Scholar
11.	Wong BC, Wong WM, Cheung KL, Tong TS, Rozen P, Young GP, Chu KW, Ho J, Law WL, Tung HM, Lai KC, Hu WH, Chan CK and Lam SK: A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther. 18:941–946. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Calogne N, Petitti DB, DeWitt TG, Dietrich AJ, Gregory KD, Harris R, Isham G, LeFevre ML, Leipzig RM, Loveland-Cherry C, Marion LN, et al U.S. Preventive Services Task Force: Screening for colorectal cancer: U.S. Preventie Services Task Force recommendation statement. Ann Intern Med. 149:627–637. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S and Tsugane S; Japan Public Health Center-based Prospective Study: Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan. Cancer Detect Prev. 31:3–11. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC and Schuman LM: The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 343:1603–1607. 2000. View Article : Google Scholar : PubMed/NCBI
15.	van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, Verbeek AL, Jansen JB and Dekker E: Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 135:82–90. 2008.
16.	Niv Y, Lev-El M, Fraser G, Abuksis G and Tamir A: Protective effect of faecal occult blood test screening for colorectal cancer: worse prognosis for screening refusers. Gut. 50:33–37. 2002. View Article : Google Scholar : PubMed/NCBI